Pascal Girard
Overview
Explore the profile of Pascal Girard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
891
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Generative models for synthetic data generation: application to pharmacokinetic/pharmacodynamic data
Jiang Y, Garcia-Duran A, Losada I, Girard P, Terranova N
J Pharmacokinet Pharmacodyn
. 2024 Aug;
51(6):877-885.
PMID: 39192091
The generation of synthetic patient data that reflect the statistical properties of real data plays a fundamental role in today's world because of its potential to (i) be enable proprietary...
2.
Milenkovic-Grisic A, Hayes S, Farrell C, Kuroki Y, Bertolino M, Venkatakrishnan K, et al.
Clin Pharmacol Ther
. 2024 Aug;
116(4):1071-1081.
PMID: 39132970
Cetuximab was initially developed and approved as a first-line treatment in patients with unresectable metastatic colorectal cancer (mCRC) for weekly administration (250 mg/m Q1W with 400 mg/m loading dose). An...
3.
Milenkovic-Grisic A, Terranova N, Mould D, Vugmeyster Y, Mrowiec T, Machl A, et al.
CPT Pharmacometrics Syst Pharmacol
. 2023 Dec;
13(1):143-153.
PMID: 38087967
This analysis aimed to quantify tumor dynamics in patients receiving either bintrafusp alfa (BA) or pembrolizumab, by population pharmacokinetic (PK)-pharmacodynamic modeling, and investigate clinical and molecular covariates describing the variability...
4.
Pitsiu M, Yalkinoglu O, Farrell C, Girard P, Vazquez-Mateo C, Papasouliotis O
CPT Pharmacometrics Syst Pharmacol
. 2023 Jun;
12(8):1157-1169.
PMID: 37332136
B cell stimulating factor (BLyS) and a proliferation-inducing ligand (APRIL) are targets for novel treatments in patients with systemic lupus erythematosus (SLE). Atacicept is a recombinant, soluble fusion protein that...
5.
Courlet P, Abler D, Guidi M, Girard P, Amato F, Violi N, et al.
CPT Pharmacometrics Syst Pharmacol
. 2023 Jun;
12(8):1170-1181.
PMID: 37328961
The development of immune checkpoint inhibitors (ICIs) has revolutionized cancer therapy but only a fraction of patients benefits from this therapy. Model-informed drug development can be used to assess prognostic...
6.
Liu H, Milenkovic-Grisic A, Krishnan S, Jonsson S, Friberg L, Girard P, et al.
CPT Pharmacometrics Syst Pharmacol
. 2023 May;
12(11):1738-1750.
PMID: 37165943
The dose/exposure-efficacy analyses are often conducted separately for oncology end points like best overall response, progression-free survival (PFS) and overall survival (OS). Multistate models offer to bridge these dose-end point...
7.
Abler D, Courlet P, Dietz M, Gatta R, Girard P, Munafo A, et al.
JCO Clin Cancer Inform
. 2023 May;
7:e2200126.
PMID: 37146261
Purpose: A semiautomated pipeline for the collection and curation of free-text and imaging real-world data (RWD) was developed to quantify cancer treatment outcomes in large-scale retrospective real-world studies. The objectives...
8.
Goteti K, French J, Garcia R, Li Y, Casset-Semanaz F, Aydemir A, et al.
CPT Pharmacometrics Syst Pharmacol
. 2022 Nov;
12(2):180-195.
PMID: 36350330
Systemic lupus erythematosus (SLE) is an autoimmune disease affecting multiple organ systems. Many investigational agents have failed or shown only modest effects when added to standard of care (SoC) therapy...
9.
Population pharmacokinetic and pharmacodynamic modeling of evobrutinib in healthy adult participants
Papasouliotis O, Mitchell D, Girard P, Dyroff M
Clin Transl Sci
. 2022 Sep;
15(12):2899-2908.
PMID: 36165192
Evobrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, has shown therapeutic potential in relapsing multiple sclerosis. This analysis aimed to develop pharmacokinetic (PK) and pharmacodynamic (PD; BTK occupancy [BTKO]) models of...
10.
Papasouliotis O, Mitchell D, Girard P, Dangond F, Dyroff M
Clin Transl Sci
. 2022 Sep;
15(12):2888-2898.
PMID: 36126241
The pharmacometric analysis of the double-blind, randomized, phase II study (NCT02975349) investigating the safety and efficacy of evobrutinib, explored exposure-response relationships and suitable dosing regimens of evobrutinib for relapsing multiple...